Perpetua Resourcesの空売り状況は、投資家がPerpetua Resourcesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Perpetua Resources (NASDAQ:PPTA) 株価情報, 空売り情報

Perpetua Resources

Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.

Perpetua Resources Corp

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) sees Q2 sales of $157.000 million-$159.000 million vs $158.34 million analyst estimate.

News

Guidance

LMND

Lemonade Sees Q2 Sales $157.000M-$159.000M vs $158.34M Est

WIIM

PLTR

Palantir Technologies shares are trading lower after the company reported Q1 financial results.

General

CANG

Cango Produced 470 Bitcoins In April Vs. 530 In March

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) raises FY2025 sales outlook from $655.00 million-$657.00 million to $661.00 million-$663.00 million vs $658.61 million estimate.

Lemonade Raises FY2025 Sales Guidance from $655.00M-$657.00M to $661.00M-$663.00M vs $658.61M Est

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.92) by 6.52 percent. This is a 28.36 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $151.20 million which beat the analyst consensus estimate of $145.21 million by 4.13 percent. This is a 26.95 percent increase over sales of $119.10 million the same period last year.

Earnings

Earnings Beats

Lemonade Q1 EPS $(0.86) Beats $(0.92) Estimate, Sales $151.20M Beat $145.21M Estimate

<ul>
<li>Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability.</li>
<li>Targeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025</li>
</ul>

Biotech

Health Care

IDYA

The FDA Clears Ideaya Biosciences' Investigational New Drug Application To Initiate A Phase 1 Trial To Evaluate IDE849 (SHR-4849), A Potential First-in-class Delta-like Ligand 3-targeting Topo-i-payload Antibody Drug Conjugate Program, In Solid Tumors

Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.96 by 16.33 percent. This is a 34.91 percent increase over earnings of $1.69 per share from the same period last year. The company reported quarterly sales of $494.28 million which beat the analyst consensus estimate of $475.98 million by 3.85 percent. This is a 14.03 percent increase over sales of $433.47 million the same period last year.

Northwest Natural Hldg Q1 Adj. EPS $2.28 Beats $1.96 Estimate, Sales $494.28M Beat $475.98M Estimate

Centerra Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGAU#NYSE">CGAU</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 14.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $299.50 million which beat the analyst consensus estimate of $290.04 million by 3.26 percent. This is a 2.06 percent decrease over sales of $305.80 million the same period last year.

CGAU

Centerra Gold Q1 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $299.50M Beat $290.04M Estimate

Centerra Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CG#TSX">CG</a>) reported quarterly earnings of $0.13 per share which met the analyst consensus estimate. This is a 13.33 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $299.50 million which beat the analyst consensus estimate of $283.02 million by 5.82 percent. This is a 2.06 percent decrease over sales of $305.80 million the same period last year.

TSX:CG

Centerra Gold Q1 Adj. EPS $0.13, Inline, Sales $299.50M Beat $283.02M Estimate

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $1.49 by 39.6 percent. This is a 49.02 percent decrease over earnings of $4.08 per share from the same period last year. The company reported quarterly sales of $701.73 million which beat the analyst consensus estimate of $690.83 million by 1.58 percent. This is a 11.50 percent decrease over sales of $792.91 million the same period last year.

ATKR

Atkore Q2 Adj. EPS $2.08 Beats $1.49 Estimate, Sales $701.73M Beat $690.83M Estimate

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.86 by 13.95 percent. This is a 27.27 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $2.06 billion which missed the analyst consensus estimate of $2.07 billion by 0.80 percent. This is a 13.04 percent increase over sales of $1.82 billion the same period last year.

Earnings Misses

KBR Q1 Adj. EPS $0.98 Beats $0.86 Estimate, Sales $2.06B Miss $2.07B Estimate

Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.70 by 8.57 percent. This is a 11.76 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $3.10 billion which beat the analyst consensus estimate of $2.89 billion by 7.02 percent. This is a 7.76 percent increase over sales of $2.87 billion the same period last year.

BALL

Ball Q1 Adj. EPS $0.76 Beats $0.70 Estimate, Sales $3.10B Beat $2.89B Estimate

Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.19 by 5.26 percent. This is a 33.33 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $329.28 million which missed the analyst consensus estimate of $344.03 million by 4.29 percent. This is a 7.43 percent decrease over sales of $355.71 million the same period last year.

CELH

Celsius Holdings Q1 Adj. EPS $0.18 Misses $0.19 Estimate, Sales $329.28M Miss $344.03M Estimate

Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.24 by 37.5 percent. This is a 65 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $458.36 million which beat the analyst consensus estimate of $451.50 million by 1.52 percent. This is a 7.42 percent decrease over sales of $495.10 million the same period last year.

Pediatrix Medical Group Q1 Adj. EPS $0.33 Beats $0.24 Estimate, Sales $458.36M Beat $451.50M Estimate

Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) affirms FY2025 Adj EPS guidance from $10.35-$10.75 to $10.35-$10.75 vs $10.68 analyst estimate. Affirms FY2025 sales outlook from $16.90 billion-$17.30 billion to $16.90 billion-$17.30 billion vs $17.13 billion estimate.

LDOS

Leidos Holdings Affirms FY2025 Adj EPS Guidance of $10.35-$10.75 vs $10.68 Est; Affirms FY2025 Sales Guidance of $16.90B-$17.30B vs $17.13B Est

Gartner Q1 Adj. EPS $2.98 Beats $2.72 Estimate, Sales $1.53B Inline

Louisiana-Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 16.99 percent decrease over earnings of $1.53 per share from the same period last year. The company reported quarterly sales of $724.00 million which beat the analyst consensus estimate of $711.08 million by 1.82 percent. This is the same as the same period last year.

Louisiana-Pacific Q1 Adj. EPS $1.27 Beats $1.19 Estimate, Net Sales $724.00M Beat $711.08M Estimate

Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 161.76 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $65.00 million which beat the analyst consensus estimate of $54.34 million by 19.61 percent. This is a 52.81 percent decrease over sales of $137.74 million the same period last year.

ESPR

Esperion Therapeutics Q1 EPS $(0.21) Misses $(0.15) Estimate, Sales $65.00M Beat $54.34M Estimate

Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) reported quarterly earnings of $2.97 per share which beat the analyst consensus estimate of $2.50 by 18.8 percent. This is a 29.69 percent increase over earnings of $2.29 per share from the same period last year. The company reported quarterly sales of $4.25 billion which beat the analyst consensus estimate of $4.10 billion by 3.50 percent. This is a 6.79 percent increase over sales of $3.98 billion the same period last year.

Leidos Holdings Q1 Adj. EPS $2.97 Beats $2.50 Estimate, Sales $4.25B Beat $4.10B Estimate

Ducommun (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.70 by 18.57 percent. This is a 18.57 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $194.11 million which beat the analyst consensus estimate of $191.98 million by 1.11 percent. This is a 1.71 percent increase over sales of $190.85 million the same period last year.

Ducommun Q1 EPS $0.83 Beats $0.70 Estimate, Sales $194.11M Beat $191.98M Estimate

Press Releases

Perpetua Resources Corp. (PPTA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Legal

Investors who lost money on Perpetua Resources Corp.(PPTA) should contact Levi & Korsinsky about pending Class Action - PPTA

PPTA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Perpetua Resources Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Perpetua Resources Shareholders Who Lost Money on Their Investment are Encouraged to Contact Johnson Fistel about the Class Action Lawsuit

PPTA Investors Have Opportunity to Lead Perpetua Resources Corp. Securities Fraud Lawsuit

Class Action Filed Against Perpetua Resources Corp. (PPTA) - May 20, 2025 Deadline to Join - Contact The Gross Law Firm

SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Perpetua Resources Corp. (NASDAQ: PPTA)

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Perpetua Resources Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PPTA

Comments

Perpetua Resources

空売り

Perpetua Resources (NASDAQ:PPTA) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル